Immunocore Archives -

Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

https://pharmaphorum.com/news/immunocore-gets-eu-nod-for-tcr-cancer-therapy-kimmtrak/

News/ News/ Oncology

Immunocore claims first-ever FDA approval for TCR cancer therapy

Phil Taylor immuno-oncology, Immunocore, Kimmtrak, Oncology, regulatory approval, TCR, uveal melanoma 0 Comment

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval

Immunocore claims first-ever FDA approval for TCR cancer therapy

https://pharmaphorum.com/news/immunocore-claims-first-ever-fda-approval-for-tcr-cancer-therapy/

Appointments/ News/ R&D

Ex-Roche, Novartis, AstraZeneca leaders appointed to biotech roles

George Underwood appointments, AstraZenenca, Immunocore, ImmunSYS, Novartis, Roche, Voyager 0 Comment

Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore

Ex-Roche, Novartis, AstraZeneca leaders appointed to biotech roles

https://pharmaphorum.com/news/ex-roche-novartis-astrazeneca-leaders-appointed-to-biotech-roles/

News/ News/ Oncology/ R&D/ UK & Europe

Immunocore’s rare cancer treatment gains UK Promising Medicine designation

Andrew McConaghie cancer, Immunocore, innovative medicine, Oncology, Promising Innovative Medicine, rare cancer 0 Comment

Immunocore has gained a Promising Innovative Medicines (PIM) designation in the UK for its candidate immunotherapy for patients with metastatic uveal melanoma, a rare tumour of the eye.

Immunocore’s rare cancer treatment gains UK Promising Medicine designation

https://pharmaphorum.com/news/immunocores-rare-cancer-treatment-gains-uk-promising-medicine-designation/

Cancer/ News/ News/ Oncology/ R&D/ UK & Europe

Immunocore hires Lilly’s Hotchkiss as chief commercial officer

Andrew McConaghie immuno-oncology, Immunocore, melanoma, UK biotech 0 Comment

UK biotech leading in the nascent field of TCR immunotherapy has appointed Andrew Hotchkiss as its new Chief Commercial Officer.

Immunocore hires Lilly’s Hotchkiss as chief commercial officer

https://pharmaphorum.com/news/immunocore-appoints-andrew-hotchkiss-chief-commercial-officer/

News/ R&D/ UK & Europe

Immunocore and GSK pick third cancer immunotherapy target

Andrew McConaghie GSK, immuno-oncology, Immunocore, TCRs 0 Comment

Immunocore, one of UK biotech’s brightest hopes, has selected a third target as part of its immuno-oncology partnership

Immunocore and GSK pick third cancer immunotherapy target

https://pharmaphorum.com/news/immunocore-gsk-pick-third-cancer-immunotherapy-target/

Clinical/ News

Immunocore’s T-cell therapy could provide HIV cure

Marco Ricci HIV, Immunocore, immunotherapy, virology 0 Comment

Treatment promises cure by reactivating immune cells to kill latent HIV-infected cells.

Immunocore’s T-cell therapy could provide HIV cure

https://pharmaphorum.com/news/revolutionary-treatment-redirects-immune-system-kill-hiv-infected-cells/

Clinical/ News/ R&D/ UK & Europe

T-cell specialist Immunocore raises $320m in private finance

Linda Banks Biotech, Immunocore, immunotherapy, UK biotech 0 Comment

Immunocore, a UK-based biotech specialising in T-cell receptor drugs has raised $320 million (£205 million), making it Europe’s

T-cell specialist Immunocore raises $320m in private finance

https://pharmaphorum.com/transversal-categories/rd/t-cell-specialist-immunocore-raises-320m-in-private-finance/

Cancer/ News/ UK & Europe

Lilly and Immunocore collaborate on novel cancer therapies

Linda Banks Immunocore, immunotherapy, UK biotech 0 Comment

Eli Lilly and Immunocore have agreed to collaborate on R&D into novel T-cell-based cancer therapies. The companies will

Lilly and Immunocore collaborate on novel cancer therapies

https://pharmaphorum.com/cancer/lilly-and-immunocore-collaborate-on-novel-cancer-therapies/

Trending

Immunocore

Login